• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional study.临床试验数据使用申请方案与相应出版物之间的一致性:一项横断面研究。
Clin Trials. 2025 Jun;22(3):279-288. doi: 10.1177/17407745241304355. Epub 2024 Dec 29.
2
Characteristics of available studies and dissemination of research using major clinical data sharing platforms.可用研究的特征和利用主要临床数据共享平台进行的研究传播。
Clin Trials. 2021 Dec;18(6):657-666. doi: 10.1177/17407745211038524. Epub 2021 Aug 18.
3
Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute-Bristol-Myers Squibb Supporting Open Access to Researchers Initiative.支持研究人员开放获取临床试验数据:杜克临床研究所 - 百时美施贵宝支持研究人员开放获取倡议。
Am Heart J. 2016 Feb;172:64-9. doi: 10.1016/j.ahj.2015.11.002. Epub 2015 Nov 14.
4
Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.大型制药公司临床试验数据共享和结果报告实践情况:改善公司实践的工具的横断面描述性研究和试点。
BMJ. 2019 Jul 10;366:l4217. doi: 10.1136/bmj.l4217.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
Data-Sharing Statements Requested from Clinical Trials by Public, Environmental, and Occupational Health Journals: Cross-Sectional Study.公共卫生、环境与职业健康期刊要求临床试验提供的数据共享声明:横断面研究
J Med Internet Res. 2025 Feb 7;27:e64069. doi: 10.2196/64069.
7
Availability and Use of Shared Data From Cardiometabolic Clinical Trials.从心脏代谢临床试验中获取和使用共享数据。
Circulation. 2018 Feb 27;137(9):938-947. doi: 10.1161/CIRCULATIONAHA.117.031883. Epub 2017 Nov 13.
8
Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal Articles.medRxiv 预印本与同行评议期刊文章中报告的临床研究结果比较。
JAMA Netw Open. 2022 Dec 1;5(12):e2245847. doi: 10.1001/jamanetworkopen.2022.45847.
9
Timely access to trial data in the context of a pandemic: the time is now.及时获取大流行背景下的试验数据:现在是时候了。
BMJ Open. 2020 Oct 29;10(10):e039326. doi: 10.1136/bmjopen-2020-039326.
10
The state of individual participant data sharing for the highest-revenue medicines.收入最高药品的个体参与者数据共享状况。
Clin Trials. 2025 Apr;22(2):170-177. doi: 10.1177/17407745241286147. Epub 2024 Oct 15.

本文引用的文献

1
Data Sharing - A New Era for Research Funded by the U.S. Government.数据共享——美国政府资助研究的新时代。
N Engl J Med. 2023 Dec 28;389(26):2408-2410. doi: 10.1056/NEJMp2308792. Epub 2023 Nov 15.
2
Estimating the prevalence of discrepancies between study registrations and publications: a systematic review and meta-analyses.评估研究注册与出版物之间差异的发生率:系统评价和荟萃分析。
BMJ Open. 2023 Oct 4;13(10):e076264. doi: 10.1136/bmjopen-2023-076264.
3
Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials.活性癌症阶段 3 随机临床试验主要终点变化的发生率。
JAMA Netw Open. 2023 May 1;6(5):e2313819. doi: 10.1001/jamanetworkopen.2023.13819.
4
Exploratory analyses in aetiologic research and considerations for assessment of credibility: mini-review of literature.病因学研究中的探索性分析和可信度评估的考虑因素:文献综述。
BMJ. 2022 May 3;377:e070113. doi: 10.1136/bmj-2021-070113.
5
Protecting against researcher bias in secondary data analysis: challenges and potential solutions.防范二次数据分析中的研究人员偏差:挑战与潜在解决方案。
Eur J Epidemiol. 2022 Jan;37(1):1-10. doi: 10.1007/s10654-021-00839-0. Epub 2022 Jan 13.
6
Characteristics of available studies and dissemination of research using major clinical data sharing platforms.可用研究的特征和利用主要临床数据共享平台进行的研究传播。
Clin Trials. 2021 Dec;18(6):657-666. doi: 10.1177/17407745211038524. Epub 2021 Aug 18.
7
Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA.《FDAAA 实施十年后:ClinicalTrials.gov 与相应出版物之间试验报告的一致性》
Trials. 2020 Jul 23;21(1):675. doi: 10.1186/s13063-020-04603-9.
8
Overview and experience of the YODA Project with clinical trial data sharing after 5 years.YODA 项目概述及五年后临床试验数据共享经验。
Sci Data. 2018 Nov 27;5:180268. doi: 10.1038/sdata.2018.268.
9
Sharing and reuse of individual participant data from clinical trials: principles and recommendations.从临床试验中分享和重用个体参与者数据:原则和建议。
BMJ Open. 2017 Dec 14;7(12):e018647. doi: 10.1136/bmjopen-2017-018647.
10
Data Sharing from Clinical Trials - A Research Funder's Perspective.临床试验中的数据共享——资助机构视角
N Engl J Med. 2017 Nov 16;377(20):1990-1992. doi: 10.1056/NEJMsb1708278.

临床试验数据使用申请方案与相应出版物之间的一致性:一项横断面研究。

Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional study.

作者信息

Vazquez Enrique, Ross Joseph S, Gross Cary P, Childers Karla, Bamford Stephen, Ritchie Jessica D, Waldstreicher Joanne, Krumholz Harlan M, Wallach Joshua D

机构信息

Yale University, New Haven, CT, USA.

Section of General Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

出版信息

Clin Trials. 2025 Jun;22(3):279-288. doi: 10.1177/17407745241304355. Epub 2024 Dec 29.

DOI:10.1177/17407745241304355
PMID:40396503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12095927/
Abstract

Background/AimsThe reuse of clinical trial data available through data-sharing platforms has grown over the past decade. Several prominent clinical data-sharing platforms require researchers to submit formal research proposals before granting data access, providing an opportunity to evaluate how published analyses compare with initially proposed aims. We evaluated the concordance between the included trials, study objectives, endpoints, and statistical methods specified in researchers' clinical trial data use request proposals to four clinical data-sharing platforms and their corresponding publications.MethodsWe identified all unique data request proposals with at least one corresponding peer-reviewed publication as of 31 March 2023 on four prominent clinical trial data sharing request platforms (Vivli, ClinicalStudyDataRequest.com, the Yale Open Data Access Project, and Supporting Open Access to Researchers-Bristol Myers Squibb). When data requests had multiple publications, we treated each publication-request pair as a unit. For each pair, the trials requested and analyzed were classified as fully concordant, discordant, or unclear, whereas the study objectives, primary and secondary endpoints, and statistical methods were classified as fully concordant, partially concordant, discordant, or unclear. For Vivli, ClinicalStudyDataRequest.com, and Supporting Open Access to Researchers-Bristol Myers Squibb, endpoints of publication-request pairs were not compared because the data request proposals on these platforms do not consistently report this information.ResultsOf 117 Vivli publication-request pairs, 76 (65.0%) were fully concordant for the trials requested and analyzed, 61 (52.1%) for study objectives, and 57 (48.7%) for statistical methods; 35 (29.9%) pairs were fully concordant across the 3 characteristics reported by all platforms. Of 106 ClinicalStudyDataRequest.com publication-request pairs, 66 (62.3%) were fully concordant for the trials requested and analyzed, 41 (38.7%) for study objectives, and 35 (33.0%) for statistical methods; 20 (18.9%) pairs were fully concordant across the 3 characteristics. Of 65 Yale Open Data Access Project publication-request pairs, 35 (53.8%) were fully concordant for the trials requested and analyzed, 44 (67.7%) for primary study objectives, and 25 (38.5%) for statistical methods; 15 (23.1%) pairs were fully concordant across the 3 characteristics. In addition, 26 (40.0%) and 2 (3.1%) Yale Open Data Access Project publication-request pairs were concordant for primary and secondary endpoints, respectively, such that only one (1.5%) Yale Open Data Access Project publication-request pair was fully concordant across all five characteristics reported. Of three Supporting Open Access to Researchers-Bristol Myers Squibb publication-request pairs, one (33.3%) was fully concordant for the trials requested and analyzed, two (66.6%) for primary study objectives, and two (66.6%) for statistical methods; one (33.3%) pair was fully concordant across all three characteristics reported by all platforms.ConclusionAcross four clinical data sharing platforms, data request proposals were often discordant with their corresponding publications, with only 25% concordant across all three key proposal characteristics reported by each platform. Opportunities exist for investigators to describe any data-sharing request proposal deviations in their publications and for platforms to enhance the reporting of key study characteristic specifications.

摘要

背景/目的

在过去十年中,通过数据共享平台对临床试验数据的再利用有所增加。几个著名的临床数据共享平台要求研究人员在获得数据访问权限之前提交正式的研究提案,这为评估已发表的分析与最初提出的目标之间的差异提供了机会。我们评估了研究人员向四个临床数据共享平台提交的临床试验数据使用申请提案中所包含的试验、研究目标、终点和统计方法与其相应出版物之间的一致性。

方法

我们在四个著名的临床试验数据共享请求平台(Vivli、ClinicalStudyDataRequest.com、耶鲁开放数据访问项目和支持研究人员开放获取——百时美施贵宝)上,识别出截至2023年3月31日所有具有至少一篇相应同行评审出版物的独特数据请求提案。当数据请求有多个出版物时,我们将每个出版物 - 请求对视为一个单元。对于每一对,所请求和分析的试验被分类为完全一致、不一致或不明确,而研究目标、主要和次要终点以及统计方法被分类为完全一致、部分一致、不一致或不明确。对于Vivli、ClinicalStudyDataRequest.com和支持研究人员开放获取——百时美施贵宝,未比较出版物 - 请求对的终点,因为这些平台上的数据请求提案并未一致报告此信息。

结果

在117对Vivli出版物 - 请求对中,76对(65.0%)所请求和分析的试验完全一致,61对(52.1%)研究目标完全一致,57对(48.7%)统计方法完全一致;35对(29.9%)在所有平台报告的三个特征上完全一致。在106对ClinicalStudyDataRequest.com出版物 - 请求对中,66对(62.3%)所请求和分析的试验完全一致,41对(38.7%)研究目标完全一致,35对(33.0%)统计方法完全一致;20对(18.9%)在三个特征上完全一致。在65对耶鲁开放数据访问项目出版物 - 请求对中,35对(53.8%)所请求和分析的试验完全一致,44对(67.7%)主要研究目标完全一致,25对(38.5%)统计方法完全一致;15对(23.1%)在三个特征上完全一致。此外,26对(40.0%)和2对(3.1%)耶鲁开放数据访问项目出版物 - 请求对分别在主要和次要终点上一致,因此只有1对(1.5%)耶鲁开放数据访问项目出版物 - 请求对在所有报告的五个特征上完全一致。在三对支持研究人员开放获取——百时美施贵宝出版物 - 请求对中,1对(33.3%)所请求和分析的试验完全一致,2对(66.6%)主要研究目标完全一致,2对(66.6%)统计方法完全一致;1对(33.3%)在所有平台报告的三个特征上完全一致。

结论

在四个临床数据共享平台中,数据请求提案与其相应出版物之间常常不一致,每个平台报告的所有三个关键提案特征中只有25%一致。研究人员有机会在其出版物中描述任何数据共享请求提案的偏差,而平台也有机会加强关键研究特征规范的报告。